|
|||||
|
|
A phase I dose‐escalation study to assess safety,tolerability, pharmacokinetics,and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma |
|
| Authors: | Johanna C. Bendell MD Robin K. Kelley MD Kent C. Shih MD Jennifer A. Grabowsky PharmD Emily Bergsland MD Suzanne Jones PharmD Thomas Martin MD Jeffrey R. Infante MD Paul S. Mischel MD Tomoo Matsutani MD PhD Shuichan Xu PhD Lilly Wong PhD Yong Liu PhD Xiaoling Wu PhD Deborah S. Mortensen PhD Rajesh Chopra MD PhD Kristen Hege MD Pamela N. Munster MD |
| Affiliation: | 1. Sarah Cannon Research Institute, Nashville, Tennessee;2. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California;3. Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, California;4. Celgene Corporation, San Diego, California;5. Celgene Corporation, Summit, New Jersey;6. Celgene Corporation, Berkeley Heights, New Jersey;7. Celgene Corporation, San Francisco, California |
| Abstract: | |
| Keywords: | AKT mTOR mTORC1/mTORC2 rapalogs |